UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
Total received in grants · trailing 12 months
$46M
$0for every U.S. household÷ 131M U.S. households
In perspective
0.0%of all $401.9B in tracked grants
11separate grants, trailing 12 months
UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION has received $46M across 11 federal grants of $1M or more on record.
Data as of August 5, 2026. Source: USAspending.gov, prime contract awards $1M+. Federal spending data lags and has known gaps. This is not a real-time or complete record.
Grants by agency
Where this recipient’s grant dollars come from.
All grant awards
Swipe to see description and amount →
| Agency | Description | Amount |
|---|---|---|
| Department of Justice | ABCD SOCIAL DEVELOPMENT (ABCD-SD) | $12,361,120 |
| Department of Health and Human Services | UNIVERSITY OF PITTSBURGH CLINICAL AND TRANSLATIONAL SCIENCE INSTITUTE - PROJECT SUMMARY THE UNIVERSITY OF PITTSBURGH (PITT) CLINICAL TRANSLATIONAL SCIENCE INSTITUTE (CTSI) WILL BUILD ON THE SUCCESS SINCE ITS FOUNDING IN 2006 OF SUPPORTING TRANSLATIONAL RESEARCH TO NOW CONDUCT RIGOROUS AND IMPACTFUL TRANSLATIONAL SCIENCE, IDENTIFYING GENERALIZABLE METHODS AND STRATEGIES THAT ACCELERATE TRANSLATIONAL RESEARCH. OUR STRATEGY IS FOR CTSI TO OPERATE AS A LEARNING RESEARCH SYSTEM THAT USES TRANSLATIONAL SCIENCE PRINCIPLES AND FRAMEWORKS TO OVERCOME BARRIERS TO THE PLANNING, CONDUCT, DISSEMINATION, OR IMPLEMENTATION OF TRANSLATIONAL RESEARCH. OUR LEARNING RESEARCH SYSTEM WILL LEVERAGE THE >700 SERVICE, CONSULTATION, AND RESOURCE REQUESTS WE RECEIVE EACH YEAR FROM PITT INVESTIGATORS TO IDENTIFY COMMON RESEARCH OBSTACLES TOWARD THE DEVELOPMENT, TESTING, AND DISSEMINATION OF GENERALIZABLE SOLUTIONS. SPECIFICALLY, WE WILL: 1) APPLY TRANSLATIONAL SCIENCE THROUGH OUR LEARNING RESEARCH SYSTEM TO SYSTEMATICALLY IMPROVE TRANSLATIONAL RESEARCH TOOLS, RESOURCES, AND EFFICIENCY; 2) CONNECT INVESTIGATORS WITH COMMUNITIES, PATIENTS, CLINICIANS, AND POLICYMAKERS TO CREATE WELL-RESOURCED AND SKILLED TEAMS WHO DELIVER IMPACTFUL TRANSLATIONAL RESEARCH; AND 3) SYSTEMATICALLY STUDY THE IMPACT OF RAPID ADVANCES IN DATA SCIENCE AND ARTIFICIAL INTELLIGENCE ON TRANSLATIONAL RESEARCH AND TRANSLATIONAL SCIENCE. WE WILL GATHER QUANTITATIVE AND QUALITATIVE DATA ON GAPS AND OPPORTUNITIES IN TRANSLATIONAL RESEARCH AND THEN CREATE AND TEST NOVEL METHODS TO ENHANCE RESEARCH EFFICIENCY, QUALITY, INNOVATION, RIGOR, AND REPRODUCIBILITY. OUR METHODS WILL INCLUDE CREATING AND REFINING AN ONTOLOGY TO CHARACTERIZE RESEARCH BARRIERS AND DEVELOPING SCALABLE MEASURES OF RESEARCH OUTPUT AND IMPACT. WITHIN THIS FRAMEWORK, WE WILL IDEATE AND ITERATIVELY REFINE SOLUTIONS THAT, IF EFFECTIVE, WE WILL DISSEMINATE BACK TO OUR INVESTIGATORS AND BEYOND. WE WILL WORK TO SEAMLESSLY INTEGRATE RESEARCH IN THE CONTEXT OF CLINICAL CARE THROUGH RESEARCH TRAINING FOR CLINICIANS, SUPPORT PRACTICE-BASED RESEARCH NETWORKS, AND EARN THE TRUST OF PATIENTS AND THE BROADER COMMUNITY BY LISTENING, ENGAGING, AND ELEVATING THEIR ROLE AS MEMBERS OF THE RESEARCH TEAM. WE WILL ALSO PROMOTE STRONG AND SUSTAINABLE BIDIRECTIONAL RELATIONSHIPS WITH A WIDE RANGE OF STAKEHOLDER GROUPS AND EXAMINE NEW WAYS TO GATHER, TRAIN, AND SUSTAIN MULTIDISCIPLINARY TEAMS. WE WILL IDENTIFY HOW AND WHEN NEW DATA SCIENCE INNOVATIONS ARE ADOPTED, HOW THEY INFLUENCE THE EFFICIENCY AND RIGOR OF TRANSLATIONAL RESEARCH, AND HOW THEY ALTER THE INTERACTIONS BETWEEN INVESTIGATORS, INDIVIDUALS, PATIENTS AND CLINICIANS. WE WILL DEVELOP, DEMONSTRATE, AND DISSEMINATE METHODS FOR USING REAL-WORLD DATA TO ADVANCE RESEARCH AND GENERATE NEW KNOWLEDGE. WE WILL DEVELOP AND TEST ANALYTIC APPROACHES TO DETECT AND MITIGATE DATA- OR AI-GENERATED THREATS TO RIGOR OR GENERALIZABILITY AND OFFER TIMELY LEARNING MODULES THAT OPTIMIZE THE ABILITY OF OUR INVESTIGATORS TO LEVERAGE THE LATEST AI TOOLS AND RESOURCES. BUILDING ON TWO DECADES OF IMPACT, CTSI ACTIVITIES MOVING FORWARD WILL HELP INTEGRATE TRANSLATIONAL RESEARCH INTO THE CULTURE OF CLINICAL OPERATIONS, INCREASE TRUSTWORTHINESS AND PARTICIPATION IN ALL STUDIES, AND PURSUE TRANSLATIONAL SCIENCE WITH GOAL-DRIVEN INTENTIONALITY TO ENABLE THESE OUTCOMES. | $10,192,245 |
| Department of Defense | MICROGLIAL BREAKTHROUGHS IN LONGEVITY, AGING, AND SENESCENCE AFTER TBI (MICROBLAST) | $6,699,872 |
| Department of Energy | NANOCRYSTAL-BASED DYADS FOR SOLAR TO ELECTRIC ENERGY CONVERSION | $3,574,676 |
| Department of Defense | GRANT | $2,665,000 |
| Department of Energy | MECHANISM OF CO2 CAPTURE IN IONIC LIQUID COMPOSITE MATERIALS | $2,564,315 |
| Department of Energy | FUSION OF LOW COST SENSORS AND DISTRIBUTED ANALYTICS FOR ENHANCED BEHIND THE METER VISIBILITY | $2,322,019 |
| Department of Health and Human Services | UNITED IMAGING UNEUROEXPLORER BRAIN PET/CT SCANNER - PROJECT SUMMARY/ABSTRACT THIS PROPOSAL REQUESTS FUNDS FOR A UNITED IMAGING UNEUROEXPLORER BRAIN PET/CT SCANNER TO SUPPORT A HIGHLY SUCCESSFUL POSITRON EMISSION TOMOGRAPHY (PET) RESEARCH PROGRAM AT THE UNIVERSITY OF PITTSBURGH. THIS VIBRANT RESEARCH PROGRAM PRESENTLY ENCOMPASSES 25 NIH-FUNDED NEUROIMAGING PROJECTS AS WELL AS SEVERAL FOUNDATION AND INDUSTRY SUPPORTED STUDIES LED BY INVESTIGATORS FROM 8 ACADEMIC DEPARTMENTS OF THE UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE. THE UNIVERSITY OF PITTSBURGH PET CENTER (UPPC) HAS BEEN OPERATIONAL SINCE 1992 AND HAS AN IMPRESSIVE RECORD OF SCHOLARLY PUBLICATION AND TRANSLATIONAL RESEARCH SUCCESS, INCLUDING DEVELOPMENT OF THE FIRST HYBRID PET/CT SCANNER AND THE AMYLOID IMAGING AGENTS [11C]PITTSBURGH-COMPOUND B (PIB) AND THE FDA- APPROVED [18F]FLUTEMETAMOL (VIZAMYL™) USED WORLDWIDE IN ALZHEIMER’S DISEASE RESEARCH, CLINICAL TRIALS, AND DIAGNOSTICS. THE REQUESTED UNEUROEXPLORER WILL REPLACE A LEGACY SIEMENS ECAT EXACT HR+ PET SCANNER WHICH WAS INSTALLED IN 1996 AND DECLARED END-OF-LIFE BY THE MANUFACTURER IN 2013. THE LIMITED SERVICEABILITY AND INFERIOR PERFORMANCE OF THE HR+ HAS BEGUN TO IMPACT PRODUCTIVITY FOR THE 10 MAJOR AND 5 OTHER USER PROJECTS DESCRIBED IN THIS PROPOSAL. ACCESS TO A MODERN, HIGH-PERFORMANCE BRAIN PET/CT SCANNER SUCH AS THE UNEUROEXPLORER, OFFERING IMPROVED SIGNAL-TO-NOISE CHARACTERISTICS, STATISTICAL QUALITY, AND QUANTITATIVE ACCURACY, IS CRITICAL TO THE CONTINUED SUCCESS OF THESE PROJECTS. AS THE ONLY COMMERCIALLY AVAILABLE PET/CT SCANNER DESIGNED EXPRESSLY FOR HUMAN BRAIN IMAGING, THE UNEUROEXPLORER IS WELL SUITED TO THE PREDOMINANTLY (~85%) NEUROSCIENCE PET IMAGING RESEARCH ENVIRONMENT OF THE UPPC. WITH A SMALL PATIENT BORE (50 CM) AND A LARGE AXIAL FOV (49.5 CM), THIS SCANNER PROVIDES SUPERIOR SOLID ANGLE COVERAGE YIELDING VERY HIGH 3D SYSTEM SENSITIVITY (46 KCPS/MBQ). A UNIQUE DETECTOR DESIGN INCLUDES DEPTH-OF-INTERACTION ENCODING AND OFFERS UNPARALLELED MAXIMUM INTRINSIC SPATIAL RESOLUTION (1.7 MM FWHM IN-PLANE) AND COUNT-RATE PERFORMANCE (PEAK NOISE EQUIVALENT COUNT RATE 1,310 KCPS @ 58 KBQ) FAR SURPASSING ANY OTHER COMMERCIALLY AVAILABLE PET/CT AND YIELDING BRAIN IMAGES WITH UNMATCHED FIDELITY. ANOTHER UNIQUE FEATURE IS A FULLY INTEGRATED 3D CAMERA SYSTEM FOR EVENT-BASED MOTION CORRECTION OF PET EMISSION DATA. THE UNEUROEXPLORER WILL BE OPERATED BY THE UPPC IN TANDEM WITH AN EXISTING SIEMENS BIOGRAPH MCT FLOW WHOLE-BODY PET/CT SCANNER INSTALLED IN 2014. NIH-FUNDED NEUROIMAGING RESEARCH WILL BE MIGRATED FROM THE MCT TO THE UNEUROEXPLORER, ENABLING COMMITMENT OF THE MCT TO THE GROWING BODY IMAGING COMPONENT OF FUNDED RESEARCH, AS WELL AS TO NEUROSCIENCE RESEARCH THAT IS NOT NIH-FUNDED. CURRENTLY THESE PROJECTS COMPETE WITH MAJOR USER PROJECTS FOR MCT SCANNER TIME, CREATING LONG SCHEDULING DELAYS. AVAILABILITY OF TWO RESEARCH-DEDICATED PET/CT SCANNERS IS CRITICAL FOR LEVERAGING THE UPPC’S PET RADIOPHARMACEUTICAL PRODUCTION CAPACITY AND MEETING THE PET SCANNER DEMANDS OF ITS USER BASE. THE REPLACEMENT OF UPPC’S LEGACY HR+ SCANNER WITH THE UNEUROEXPLORER WILL RESULT IN A GREATER STUDY OUTPUT AND WILL SUPPORT CONTINUED EXPANSION OF THE SCOPE OF PET IMAGING RESEARCH CONDUCTED AT THE INSTITUTION. | $2,000,000 |
| Department of Health and Human Services | INTERORGANELLAR CALCIUM SIGNALING IN HEALTH AND DISEASE - PROJECT SUMMARY CALCIUM (CA2+) SIGNALING IS INTIMATELY LINKED TO LIFE ON EARTH; EVERY CELL IS TOUCHED BY CA2+ SIGNALING AT A MOMENT OF ITS EXISTENCE. WHILE CA2+ INFLUX ACROSS THE PLASMA MEMBRANE (PM) IS CRUCIAL TO VIRTUALLY EVERY CELLULAR FUNCTION, ITS (PATHO)PHYSIOLOGICAL IMPACT CANNOT BE FULLY APPRECIATED WITHOUT CONSIDERING ITS PROPAGATION TO INTERNAL ORGANELLES. IN FACT, THE EMERGENCE OF EUKARYOTES, MITOCHONDRIA AND ENDOMEMBRANES, INCLUDING THE ENDOPLASMIC RETICULUM (ER), GOLGI AND ENDOLYSOSOMES IS INTRICATELY COUPLED TO THE CONCOMITANT RISE OF SOPHISTICATED CA2+ SIGNALING MECHANISMS. ORGANELLES TAKE UP AND EXTRUDE CA2+ AT DISCRETE MEMBRANE CONTACT SITES NEAR THE PM AND OTHER ORGANELLES, GENERATING HIGHLY LOCALIZED CA2+ SIGNALING MICRODOMAINS. THE SPATIOTEMPORAL GENESIS OF THESE MICRODOMAINS THROUGH TIGHTLY COORDINATED INTERORGANELLAR CA2+ TRANSPORT, THEIR IMPACT ON TRANSCRIPTION AND METABOLISM AND THEIR CONVERGENCE ON THE REGULATION OF VASCULAR AND AIRWAY TISSUE FUNCTION IN HEALTH AND DISEASE ARE LARGELY UNKNOWN. OUR OVERARCHING HYPOTHESIS IS THAT DYNAMIC AND COORDINATED INTERACTIONS AMONG THE PM, ER, MITOCHONDRIAL, AND LYSOSOMAL CA2+ CHANNELS ESTABLISH CRITICAL CA2+ SIGNALING MICRODOMAINS THAT REGULATE TRANSCRIPTIONAL AND METABOLIC PROGRAMS ESSENTIAL FOR TISSUE HOMEOSTASIS, WHILE DYSREGULATION OF THIS CROSSTALK CONTRIBUTES TO METABOLIC, VASCULAR AND AIRWAY DISEASE. WE FOCUS ON FOUR SETS OF CA2+ CHANNELS/TRANSPORTERS THAT SIGNAL AT THE INTERFACE OF THE PM (ORAIS), ER (STIMS), MITOCHONDRIA (MCU/NCLX) AND LYSOSOMES (TRPML1). ORAIS ARE PM CHANNELS ENCODED BY THREE SEPARATE GENES (ORAI1-3) AND PHYSICALLY ACTIVATED BY STIM1/STIM2 PROTEINS AT PM-ER JUNCTIONS. CA2+ INFLUX THROUGH PM ORAIS PROPAGATES INTO ORGANELLES TO SUPPORT CRITICAL ORGANELLAR FUNCTIONS. RECIPROCALLY, CA2+ UPTAKE AND EXTRUSION BY ORGANELLES SHAPES CYTOSOLIC CA2+ MICRODOMAINS TO MODULATE TRANSCRIPTION. OUR IN VIVO DATA SUPPORT CRITICAL INVOLVEMENT OF SPECIFIC CA2+ SIGNALING PROTEINS AT THE PM-ER-MITOCHONDRIA-LYSOSOME NEXUS, IN REGULATING GENE AND METABOLIC PROGRAMS CRUCIAL TO VASCULAR AND AIRWAY REMODELING DURING DISEASE. THEREFORE, WE AIM TO UNDERSTAND THE MECHANISMS OF INTERORGANELLAR CA2+ SHUTTLING AND THE MOVEMENTS AND INTERACTIONS OF THE CHANNELS/PROTEINS INVOLVED, THEIR FUNCTION IN NORMAL PHYSIOLOGY AND THEIR POTENTIAL AS THERAPEUTIC TARGETS OF VASCULAR AND AIRWAY DISEASE. OUR GOAL IS TO ADDRESS TWO FUNDAMENTAL QUESTIONS: 1) WHAT ARE THE BASIC MECHANISMS OF NATIVE ORAI1-2-3/STIM1-2 CA2+ CHANNEL CHOREOGRAPHY, INCLUDING ISOFORM MOVEMENT, ASSOCIATION, DISSOCIATION AND INTERNALIZATION AT PM-ER JUNCTIONS, THEIR ROUTES OF COMMUNICATION WITH MITOCHONDRIAL AND LYSOSOMAL CA2+ CHANNELS AND HOW THESE INTERACTIONS SHAPE CYTOSOLIC CA2+ SIGNALS, GENE TRANSCRIPTION AND METABOLIC ACTIVITY; AND 2) WHAT ARE THE FUNCTIONS OF THESE CA2+ CHANNEL ISOFORMS IN SUPPORTING TISSUE PHYSIOLOGY, AND THE CONTRIBUTION OF THEIR ALTERED ACTIVITY TO OBESITY, HYPERTENSION AND VASCULAR REMODELING USING MOUSE MODELS. OUR WORK, WHICH APPLIES BROADLY TO ALL CELL TYPES, WILL PROVIDE CRUCIAL INSIGHTS INTO CA2+ CHANNEL REGULATION OF KEY SIGNALING PATHWAYS AND GENE AND METABOLIC PROGRAMS THAT ARE ESSENTIAL FOR HEALTHY PHYSIOLOGY AND WILL IDENTIFY SOME OF THESE MECHANISMS AS NOVEL TARGETS FOR DISEASE THERAPY. | $1,088,692 |
| Department of Health and Human Services | CTSA K12 PROGRAM AT UNIVERSITY OF PITTSBURGH - PROJECT SUMMARY/ABSTRACT TO DEVELOP THE NEXT GENERATION OF EXPERTS IN CLINICAL AND TRANSLATIONAL RESEARCH AND TRANSLATIONAL SCIENCE, K12 PROGRAMS MUST CONTINUALLY ADAPT TRAINING OPPORTUNITIES AND RESOURCES. CLINICAL AND TRANSLATIONAL RESEARCH IS ABOUT MOVING RESEARCH TO THE NEXT PHASE OF THE TRANSLATIONAL PROCESS, WHILE TRANSLATIONAL SCIENCE IS THE FIELD OF GENERATING INNOVATIVE APPROACHES TO OVERCOME BARRIERS WITHIN CLINICAL AND TRANSLATIONAL RESEARCH, RESULTING IN CONDUCTING CLINICAL AND TRANSLATIONAL RESEARCH MORE EFFICIENTLY AND EFFECTIVELY. AT THE UNIVERSITY OF PITTSBURGH, WE HAVE TRAINED SCIENTISTS WITH OUR MASTER OF SCIENCE DEGREE AND CERTIFICATE IN CLINICAL RESEARCH SINCE 2000, BEGINNING WITH THE K30 AWARD. RECEIVING THE NIH CLINICAL AND TRANSLATIONAL SCIENCE AWARD IN 2006 ENABLED US TO DEVELOP EXTENSIVE TRAINING AND CAREER DEVELOPMENT PROGRAMS FOR CLINICAL AND TRANSLATIONAL RESEARCH INVESTIGATORS, INCLUDING MEDICAL AND GRADUATE STUDENTS, POSTDOCTORAL FELLOWS, AND FACULTY MEMBERS. OUR PREMIER PROGRAM IS THE KL2 SCHOLARS PROGRAM, NOW IN ITS 21ST YEAR, HAVING STARTED AS A ROADMAP K12 IN 2004. THIS PROGRAM EMPHASIZES MULTIDISCIPLINARY MENTORING, MENTORED RESEARCH EXPERIENCES, CORE CAREER DEVELOPMENT TRAINING COMPLEMENTED WITH INDIVIDUALIZED TRAINING, AND GRANT WRITING SKILLS. AS WE TRANSITION FROM OUR PAST KL2 PROGRAM TO THE NEW K12 CAREER DEVELOPMENT PROGRAM, OUR OVERARCHING AIM IS TO PREPARE THE NEXT GENERATION OF TRANSLATIONAL SCIENTISTS SO THAT THEY CAN OVERCOME BARRIERS IN THE CLINICAL AND TRANSLATIONAL RESEARCH PATHWAY AND DELIVER MORE TREATMENTS TO MORE PATIENTS MORE QUICKLY. SPECIFICALLY, WE WILL 1) TRAIN SCHOLARS IN THE TRANSLATIONAL SCIENCE AND DOMAIN-SPECIFIC SKILLS NEEDED TO BE SUCCESSFUL CLINICAL AND TRANSLATIONAL RESEARCHERS AND TRANSLATIONAL SCIENTISTS; 2) PROVIDE CROSS-DISCIPLINARY CAREER DEVELOPMENT SUPPORT TO SCHOLARS IN LEADERSHIP, MANAGEMENT, AND NETWORK-BUILDING SO THAT THEY DEVELOP THE KNOWLEDGE, SKILLS, AND COMMUNITIES NEEDED TO THRIVE AS TRANSLATIONAL SCIENTISTS AND LEADERS; AND 3) OPTIMIZE MULTIDISCIPLINARY MENTORING OF SCHOLARS SO THAT THEY THRIVE AS MENTEES AND AS FUTURE MENTORS. SCHOLAR APPOINTMENTS WILL BE 2 YEARS IN DURATION, WITH THE POSSIBILITY OF A THIRD YEAR. ACCOMPLISHING OUR AIMS WILL RESULT IN DEVELOPING A NEW GENERATION OF TRANSLATIONAL RESEARCHERS AND SCIENTISTS WHO WILL BE LEADERS IN THEIR FIELDS. OUR PROGRAM HAS AN OUTSTANDING TRACK RECORD OF LAUNCHING SCHOLARS TO IMPACTFUL INDEPENDENT INVESTIGATOR CAREERS, AND OUR COMMITMENT TO DEVELOPING AND EVOLVING THE COMPONENTS OF OUR LONG-STANDING PROGRAM WILL FURTHER PREPARE OUR SCHOLARS FOR SUCCESSFUL CAREERS IN CLINICAL AND TRANSLATIONAL RESEARCH. | $1,025,770 |
| Department of Health and Human Services | THE HYPERTENSION TOOLKIT: AN ADAPTIVE MOBILE HEALTH BLOOD PRESSURE INTERVENTION - HYPERTENSION (HTN) IS THE FOREMOST MODIFIABLE CAUSE OF CARDIOVASCULAR MORBIDITY AND MORTALITY. WE HAVE PARTNERED WITH COMMUNITY-BASED AND FEDERALLY QUALIFIED HEALTH CENTERS TO DEVELOP A RANDOMIZED CLINICAL TRIAL TO ADDRESS BLOOD PRESSURE (BP) TREATMENT, MANAGEMENT, AND CONTROL IN LIMITED-RESOURCE PRIMARY CARE SETTINGS. OUR MULTILEVEL HTN TOOLKIT PROVIDES THEORY-INFORMED CHRONIC DISEASE SELF-MANAGEMENT (CDSM), AND CONSISTS OF HTN EDUCATION, GUIDANCE ON NON-PHARMACOLOGIC AND LIFESTYLE APPROACHES, SUPPORT FOR LONGITUDINAL HOME- BLOOD PRESSURE MONITORING (HBPM), AND ENHANCED HTN TREATMENT. ALL TRIAL PARTICIPANTS (N=378) RECEIVE HBPM AND A CDSM WORKBOOK. INTERVENTION PARTICIPANTS RECEIVE OUR VALIDATED HTN VIRTUAL COACH THAT GUIDES CDSM, CONNECTS WITH HBPM RESULTS, AND FACILITATES SELF-EFFICACY. THE STUDY EMPLOYS A SEQUENTIAL MULTIPLE ASSIGNMENT RANDOMIZED TRIAL (SMART) DESIGN, SUCH THAT NON-RESPONDERS (INTERVENTION OR ENHANCED USUAL CARE PARTICIPANTS WITH SYSTOLIC BP≥130 MM HG) AT EITHER A 2- OR 4-MONTH HOME-SUPERVISED BP VISIT ARE RE-RANDOMIZED TO RECEIVE AUGMENTED HTN TOOLKIT TACTICS: (1) MODEST AUGMENTATION, OUR TEXT-BASED DIGITAL HEALTH PROGRAM, DEMONSTRATED TO SUPPORT HBPM; OR (2) VIGOROUS AUGMENTATION, TEXT-BASED DIGITAL HEALTH PLUS PHARMACIST CO- MANAGEMENT OF HTN THERAPY. WE HAVE DEVELOPED A COMMUNITY ENGAGEMENT COLLABORATIVE (CEC) IN CONCERT WITH OUR PARTNER CLINICS TO GUIDE THE STUDY DESIGN AND TOOLKIT ELEMENTS. IN THE R61 PHASE, OUR CEC WILL REVIEW STUDY MATERIALS; WE WILL TAILOR OUR VIRTUAL AGENT, GUIDED BY THE CEC AND PARTNER CLINICS; COORDINATE WITH THE CLINICS; AND LAUNCH THE TRIAL. AS R33 PHASE AIMS, WE WILL: (AIM 1) DETERMINE THE 6-MONTH EFFECT OF THE VIRTUAL AGENT AS OUR PRIMARY OUTCOME. AS SECONDARY OUTCOMES WE WILL DETERMINE (A) THE OPTIMAL AUGMENTATION TACTIC (MODEST [TEXTS] VS VIGOROUS [TEXTS PLUS PHARMACIST CO-MANAGEMENT]) TO ADDRESS SBP NON-RESPONSE AND (B) THE EFFECTS OF THE HTN VIRTUAL AGENT AND AUGMENTATION TACTICS AT 12 MONTHS. (AIM 2) QUANTIFY THE BUDGET IMPACT AND COST-EFFECTIVENESS OF THE HTN TOOLKIT AND AUGMENTATION TACTICS. WE WILL APPLY THE HIGHLY VALIDATED BP- CARDIOVASCULAR DISEASE POLICY MODEL TO ESTIMATE THE 1- AND 10-YEAR EFFECTS ON BP CONTROL, EVENTS PREVENTED, PROGRAM AND HEALTH CARE COSTS, AND QUALITY-ADJUSTED LIFE YEARS. (AIM 3) EVALUATE THE IMPLEMENTATION PROCESS OF THE HTN TOOLKIT WITH QUALITATIVE ASSESSMENTS OF PARTICIPANTS AND PARTNER CLINIC PROVIDERS AND LEADERSHIP AS GUIDED BY THE CONSOLIDATED FRAMEWORK FOR IMPLEMENTATION RESEARCH 2.0. WE WILL CONDUCT AN EXPLANATORY SEQUENTIAL MIXED METHODS DESIGN TO IDENTIFY POTENTIAL MECHANISMS OF EFFECT OF THE HTN TOOLKIT AND ITS BARRIERS, FACILITATORS, AND CONTEXT. EXPECTED RESULTS: OUR MULTIDISCIPLINARY TEAM IN CONCERT WITH OUR CEC AND PARTNER CLINICS HAS EXPERTISE IN HBPM APPLICATION, CLINICAL TRIALS, SMART DESIGN, BUDGET IMPACT FOR HTN INTERVENTIONS, COMMUNITY ENGAGEMENT, AND IMPLEMENTATION. WE WILL EVALUATE A SCALABLE, PATIENT-CENTERED INTERVENTION TO IMPROVE HTN CONTROL IN RESOURCE-LIMITED SETTINGS SUCH AS OUR PARTNER CLINICS. IF PROVEN SUCCESSFUL, THIS INTERVENTION CAN BE BROADLY DISSEMINATED TO IMPROVE HTN CARE AND MANAGEMENT. | $1,019,556 |